Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Hutchmed China to make several presentations at cancer research meeting
(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California. The AIM-traded firm said one of the highlights would be the initial preclinical data on HMPL-506, a novel and highly potent menin-MLL inhibitor developed for treating certain types of acute leukaemia.
Notably, HMPL-506 showed stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukaemia cell line models compared to five other menin inhibitors in clinical development.
Additionally, when combined with azacytidine, venetoclax, or gilteritinib, HMPL-506 synergistically improved the anti-tumour effect against MLL-rearranged leukemias, both in vitro and in vivo.
The company said the investigational drug candidate showed favourable pharmacokinetic profiles, high selectivity, and a low risk of cardiac toxicity.
It said plans were underway for a phase one study of HMPL-506 in the second half of 2024.
Another significant presentation would feature initial preclinical data on HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC) where daratumumab was conjugated with cytotoxic payload monomethyl auristatin E (MMAE) via a novel linker.
The ADC demonstrated significant superior anti-tumor activity to daratumumab, Hutchmed explained, including in several B-cell malignancies models resistant to daratumumab treatment.
Additional presentations would cover preclinical data on the ERK 1/2 inhibitor, HMPL-295; early clinical data on the Syk inhibitor, sovleplenib, in lymphoma patients; as well as further clinical data from global studies of VEGFR inhibitor, fruquintinib, and MET inhibitor, savolitinib.
Various investigator-initiated studies on fruquintinib and VEGFR/CSF-1R/FGFR inhibitor, surufatinib, would also be presented, the company added.
At 1208 BST, shares in Hutchmed China were down 2.24% at 261.01p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
